AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00322101 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT00944645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: niacin (+) laropiprant (Source 2)
Description: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
Study NCT02619838 — intervention group
Intervention type: DEVICE
Intervention: Aptus CCS 5.0 or/and 7.0 screws
Description: Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
Study NCT03785717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROG
Description: Bone width augmentation using bone grafting and membrane non cross linking.
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or orally
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT03785717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROG & ESWT
Description: Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
Study NCT02659111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensive Functional Exercise (HIFE)
Description: Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
Study NCT02659111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training advice
Description: Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
Study NCT02659111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training advice
Description: Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
Study NCT04446936 — intervention group
Intervention type: PROCEDURE
Intervention: Flap covering for pressure ulcer
Description: Flap covering for pressure ulcer
Study NCT02463968 — intervention group
Intervention type: PROCEDURE
Intervention: Venipuncture for blood draw
Description: Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
Study NCT01386034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrulline and placebo
Description: After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
Study NCT02633241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine bolus and high infusion-Propofol
Description: First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
Study NCT02633241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine bolus and low infusion-Propofol
Description: First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
Study NCT02633241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine bolus only - Propofol
Description: First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
Study NCT04161573 — intervention group
Intervention type: BEHAVIORAL
Intervention: Watching ironic stories
Description: All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
Study NCT03211598 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE with Surefire
Description: Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
Study NCT01348321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole
Description: Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
Study NCT00003311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00003311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT02463968 — intervention group
Intervention type: PROCEDURE
Intervention: Arthrocentesis for synovial fluid draw
Description: Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
Study NCT02721550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: 800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
Study NCT02990078 — intervention group
Intervention type: DRUG
Intervention: Sildenafil citrate
Description: Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
Study NCT02990078 — intervention group
Intervention type: DEVICE
Intervention: Functional Near Infared Spectroscopy
Description: Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
Study NCT02990078 — intervention group
Intervention type: OTHER
Intervention: Hypercapnia Challenge
Description: The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
Study NCT00732160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (A)
Description: Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Study NCT00732160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Infusion (V)
Description: Vehicle infusion for 12.5 hours
Study NCT01580358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shen-Mai San
Description: Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
Study NCT01580358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
Study NCT03145363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
Study NCT00732160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet (HS)
Description: 160 mmol/d sodium diet for 7 days
Study NCT00732160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Description: 20 mmol/d sodium diet for 9 days
Study NCT03145363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough).
Study NCT02256072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plan Your Lifespan Website
Description: Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
Study NCT02256072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Go4Life Website
Description: Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
Study NCT04384497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
Study NCT01610401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 mg three times a day, for 3 days
Study NCT01610401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pretreatment with metformin in combination of infusion of caffeine.
Description: Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
Study NCT01610401 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No pretreatment with metformin in combination with infusion of caffeine
Description: No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
Study NCT02795962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct transfer to an Endovascular Center
Description: Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
Study NCT02648269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-110
Study NCT02648269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-212
Study NCT02648269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-037
Study NCT04206007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06
Description: Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
Study NCT01297920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study NCT01297920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%
Study NCT01297920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study NCT05548673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
Study NCT02940080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - 21 day cycle
Description: Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin.
Description: Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin.
Description: Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
Study NCT01631903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 12 mg
Description: 12 mg, vaginal capsule, once daily for 4 months
Study NCT01631903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 3 mg
Description: 3 mg, vaginal capsule, once daily for 3 months
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel.
Description: Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel.
Description: Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - 28 day cycle
Description: Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 30mg
Description: YH4808 30mg (single dose)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 50mg
Description: YH4808 50mg (single dose)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100mg
Description: YH4808 100mg (single dose)
Study NCT03678883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
Study NCT04252365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given i.v.
Study NCT04252365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given i.v.
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 200mg
Description: YH4808 200mg (single dose)
Study NCT02507973 — intervention group
Intervention type: OTHER
Intervention: Airway Pressure Release Ventilation
Description: Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
Study NCT02507973 — intervention group
Intervention type: OTHER
Intervention: Low Tidal Volume Ventilation
Description: After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
Study NCT03239158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03239158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03239158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03239158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03714308 — intervention group
Intervention type: DRUG
Intervention: Ivt. Aflibercept (Eylea, BAY86-5321)
Description: Treatment is applied according to routine clinical practice and independent of the study setting.
Study NCT02519465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min